Amgen's Q2 2026 Results: The Impact of Biosimilars and Drug Pricing Policies

In a pivotal moment for the pharmaceutical industry, Amgen's second-quarter results for 2026 reveal a landscape undergoing significant transformation due to the competitive entry of biosimilars and the implementation of government drug pricing regulations. The Thousand Oaks, California-based biotech giant reported total revenues of $10.1 billion for the quarter, marking a 10% increase from the previous year. This growth, however, was accompanied by notable declines in sales for some of its flagship products, illustrating the dual pressures of new market entrants and regulatory changes. As the industry adapts, understanding these dynamics will be crucial for stakeholders across the spectrum—from pharmaceutical companies to healthcare providers and consumers.

Amgen's financial metrics for Q2 2026 tell a complex story. While product sales increased by 9%, the company experienced a dramatic 65% rise in GAAP diluted earnings per share, climbing to $4.37. In contrast, its non-GAAP diluted EPS showed a modest increase of 4%, reaching $6.29. These figures highlight the contrasting pressures of rising revenues and the significant impact of competition and pricing regulations on profit margins. This article explores how the advent of biosimilars and the Inflation Reduction Act (IRA) is reshaping the drug spending landscape, with critical implications for benefits brokers and employer plan sponsors.

Biosimilars: A Game Changer in the Pharmaceutical Market

The rise of biosimilars has been transformative for the pharmaceutical sector. These biologic medical products, which are similar to already-approved reference products, offer a pathway for competition that can lead to reduced costs for consumers and insurers alike. Amgen's results reflect this reality, as several of its key products faced substantial revenue declines due to the entry of biosimilars into the market.

Revenue Impact of Biosimilars

Two of Amgen's prominent biologics, Prolia and XGEVA, saw staggering year-over-year sales declines of 32% and 34%, respectively. The company attributes these decreases mainly to lower volume and net selling prices, a direct consequence of multiple biosimilars launching globally. Furthermore, the decline in Enbrel, a long-standing leader in the inflammation category, underscores the challenges faced by established brands in the face of new competition. Enbrel's overall sales dropped by 4%, with its net selling price plummeting by 22%—a clear indication that biosimilar entry is having a profound impact.

The Inflation Reduction Act and Its Implications

Equally significant is the role of the Inflation Reduction Act (IRA), which introduced a new pricing structure for Medicare Part D drugs. Effective January 1, this legislation allows the government to negotiate maximum fair prices for high-expenditure Part D drugs, marking a historic shift in how drug prices are determined in the U.S. According to the Centers for Medicare and Medicaid Services (CMS), the IRA's Medicare Drug Price Negotiation Program set these prices for ten high-expenditure drugs in 2026, creating a new reality for pharmaceutical manufacturers.

Effects on Specialty Medications

Specialty medications, which represent a small percentage of total prescriptions but a significant portion of overall spending, are now under the microscope. Data from Benefitfocus covering around 600,000 members revealed that specialty medications accounted for only 14% of prescriptions filled in 2025, yet they constituted a staggering 87.6% of total prescription spending. This discrepancy highlights the urgent need for effective cost-containment strategies, especially as biosimilars enter the market and pricing regulations take effect.

• **Biosimilars are fundamentally changing the competitive landscape for established biologics.**
• **The IRA introduces a new layer of complexity to drug pricing negotiations.**
• **Employers must adapt to rising costs associated with specialty medications.**

The Role of Benefits Brokers and Employer Plan Sponsors

As the pharmaceutical market evolves, benefits brokers and employer plan sponsors must navigate this changing landscape to manage healthcare costs effectively. The introduction of biosimilars and the IRA's price-setting mechanism offers both challenges and opportunities. Brokers play a vital role in advising employers on formulary strategies that include biosimilars, which can help mitigate the financial impact of escalating drug costs.

Strategic Formulary Considerations

Employers may need to reassess their formularies to incorporate biosimilars, which can offer substantial savings. By doing so, they can potentially reduce their overall prescription spending while maintaining access to necessary treatments for employees. As the market adapts, brokers can leverage data and analytics to inform their clients about the best strategies for incorporating biosimilars into their health plans and negotiating favorable terms with pharmaceutical manufacturers.

Looking Ahead: Amgen's Future Outlook

Amgen's outlook for the remainder of 2026 remains cautiously optimistic. The company expects total revenues to range between $38.2 billion and $39.4 billion, alongside a projected non-GAAP EPS of $22.30 to $23.50. Notably, Amgen is advancing its new drug, MariTide, through multiple Phase 3 studies. This antibody-peptide conjugate targets the GLP-1 receptor and GIPR, addressing obesity and related conditions such as type 2 diabetes and cardiovascular outcomes.

Potential Market Disruption

If successful, MariTide could disrupt the market landscape, especially given the existing cost pressures from GLP-1 medications. The 2026 Amwins Benefits State of the Market report noted that some employers are adding over 2% to their healthcare budgets solely due to the rising costs associated with these medications. The introduction of a new entrant with a competitive monthly dosing profile could significantly influence formulary negotiations and employer strategies going forward.

Key Takeaways

• Amgen's Q2 2026 results indicate a pharmaceutical market heavily influenced by biosimilar competition and new pricing regulations.
• The IRA's drug price negotiation program is now operational, setting a precedent for future negotiations.
• Benefits brokers must adapt their strategies to address the rising costs of specialty medications.
• Formulary strategies incorporating biosimilars can be crucial for employers looking to manage healthcare expenses.
• Amgen's pipeline, including MariTide, holds potential for future market disruption and cost implications.

Frequently Asked Questions

What are biosimilars and how do they differ from traditional drugs?

Biosimilars are medications that are highly similar to already-approved biologic products, which are made from living organisms. Unlike traditional drugs, which are typically small molecules and have well-defined structures, biologics are larger, more complex molecules. Biosimilars offer an opportunity for competition in the market, potentially lowering costs for consumers and insurers by providing alternatives to high-cost reference products.

How does the Inflation Reduction Act affect drug pricing?

The Inflation Reduction Act allows the government to negotiate prices for certain high-expenditure drugs covered under Medicare Part D. This program aims to set maximum fair prices, thereby reducing costs for consumers and taxpayers. The first negotiations took effect in 2026, marking a significant shift in how drug prices are determined in the U.S. This could lead to lower out-of-pocket costs for patients and reduced premiums for employers providing health insurance.

What strategies can employers use to manage rising healthcare costs?

Employers can employ several strategies to manage rising healthcare costs, including incorporating biosimilars into their formularies, negotiating better terms with pharmaceutical manufacturers, and leveraging data analytics to inform decision-making. Additionally, employers should consider wellness programs and preventive care options, as these can lead to long-term savings by reducing the overall burden of healthcare costs.

What is Amgen's future outlook regarding its revenue and product pipeline?

Amgen's future outlook for 2026 suggests a cautious optimism with projected revenues ranging from $38.2 billion to $39.4 billion. The company is also advancing new products, such as MariTide, which targets obesity and related conditions. If successful, this could further enhance Amgen's market position and provide new opportunities for addressing healthcare costs associated with specialty medications.